Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint

CERUS CORP

2024-Q1 EPS reported -$0.05

Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).
Net loss $9.7M ($0.05 EPS) vs $15.6M ($0.09) in Q1 2023; adjusted EBITDA -$2.7M.
ReCePI Phase 3 trial for INTERCEPT Red Blood Cells met primary endpoint in cardiovascular surgery.
FDA approved 12-month shelf life for INTERCEPT Platelet Processing Sets.
FY2024 product revenue guidance reaffirmed at $172-175M; IFC guidance $8-10M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CERUS CORP updated its first quarter ended March 31, 2024 guidance (reaffirmed).

Period: first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 2, 2024, Cerus Corporation (the “Company”) announced its financial results for its first quarter ended March 31, 2024.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

CERUS CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-052053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.